<DOC>
	<DOCNO>NCT00324961</DOCNO>
	<brief_summary>This phase IV , 2-year , multi-center , single arm open-label study , evaluate efficacy safety use local manufacture adefovir dipivoxil Chinese subject HBeAg negative chronic hepatitis B</brief_summary>
	<brief_title>Adefovir Dipivoxil Tablets ( 10mg ) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Male female subject age 18‑65 year inclusive Documented chronic hepatitis B infection determine presence serum HBsAg least 6 month Documented HBeAg negative HBeAb positive screen visit least 6 month history HBeAg negativity . Serum HBV DNA ≥ 104 copies/mL ( Roche COBAS AMPLICORTM HBV MONITOR Test , LLOD 300 copies/mL ) study screen ( within 4 week baseline ) ALT value ≥1.3 time upper limit normal ( ULN ) time screen , determine use laboratory range document ALT abnormal within 6 month prior study screen . Serum alpha fetoprotein ( AFP ) &lt; 50 ng/mL first screen visit . If AFP level ≥ 50 ng/mL decline &lt; 50 ng/mL screen baseline , patient eligible . Compensated liver disease follow laboratory clinical parameter study screen : Prothrombin time ≤ 2 second normal range . Albumin ≥ 35 g/L . Total bilirubin ≤ 2.5 mg/dL ( ≤ 43 µmol/L ) normal direct bilirubin . No history variceal bleeding . No history encephalopathy . No history ascites Adequate renal function define serum creatinine ≤ 1.5 mg/dL ( ≤ 130 µmol/L ) . Adequate hematological function define : Absolute neutrophil count ≥ 1 x 10³/mm³ ( ≥ 1 x 10^9/L ) ; Platelets ≥ 80 x 10³/mm³ ( ≥ 80 x 10^9/L ) ; Platelets ≥ 100 x 10³/mm³ ( ≥ 100 x 10^9/L ) recommend patient undergo liver biopsy . Hemoglobin ≥ 10 g/dL ( ≥ 100 g/L ) ( male ) ≥ 9 g/dL ( ≥ 9 g/L ) ( female ) . Willing able undergo minimum two liver biopsy ( prior dosing , 104 week therapy ; apply subject enrol site liver biopsy require ) . A female eligible enter participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female premenarchal postmenopausal ) ; 2. childbearing potential negative serum pregnancy test screen , agree one following : Complete abstinence intercourse 2 week prior administration study drug , throughout study , time interval completion premature discontinuation study account elimination investigational drug , ( minimum 5 halflives longer pharmacodynamic profile investigational drug warrant long time period ) ; , Female sterilization ; , Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Any method publish data show low expected failure rate method le 1 % per year ; , Barrier method use combination acceptable method . Agree participate investigational trial undertake HBV systemic antiviral regimen participation study Able give write informed consent comply requirement study Any serious active medical psychiatric illness hepatitis B , opinion investigator , would interfere patient treatment , assessment compliance protocol . This would include , may limit , renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection cancer . Documented evidence active liver disease due cause include coinfection hepatitis C ( HCV ) , Subjects antiHCV positive HCV RNA undetectable consider HCV seropositive eligible ; coinfection hepatitis delta ( HDV ) ; coinfection HIV ; autoimmune hepatitis ( antinuclear antibody titre &gt; 1:160 ) Clinical sign decompensated liver disease baseline . These may include limited : serum bilirubin &gt; 2.5 mg/dL ( ≤ 43 µmol/L ) prothrombin time &gt; 2 second prolong ULN serum albumin &lt; 35g/L history ascites , variceal bleeding , encephalopathy Alanine aminotransferase ( ALT ) &gt; 10 time ULN screen history acute exacerbation lead transient decompensation Hepatocellular carcinoma evidence one following : suspicious focus ultrasound radiological examination positive ultrasound finding , serum alphafetoprotein &gt; 100ng/mL Active alcohol drug abuse history alcohol drug abuse consider investigator sufficient hinder compliance treatment , participation study interpretation result . Use immunosuppressive therapy , immunomodulatory therapy ( include interferon thymosin ) , systemic cytotoxic agent , chronic antiviral agent exclude lamivudine ( e.g . ganciclovir , adefovir dipivoxil , entecavir , famciclovir , FTC , DAPD , LFMAU , HBIg ) , Chinese herbal medicine know activity HBV within previous 12 month study ; use agent effect ALT reduction ( e.g . schisandra agent ) study Use lamivudine within previous 3 month study Planned liver transplantation previous liver transplantation Received hepatotoxic drug ( e.g. , anabolic steroid , ketaconazole , itraconazole , isoniazid , rifampin , rifabutin ) within 2 month prior study screen expect receive course study . Received nephrotoxic drug ( e.g. , aminoglycosides , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine etc . ) competitor renal excretion ( e.g. , probenecid ) within 2 month prior study screen expectation patient receive course study . Receiving systemic ( intravenous oral ) steroid , immunosuppressant therapy chemotherapeutic agent within 2 month study screen expect receive agent course study . History hypersensitivity nucleoside and/or nucleotide analogue . Inability comply study requirement . Lactating female female positive serum pregnancy test . Organ bone marrow transplant recipient . Previous ( plan ) participation investigational trial involve administration investigational compound within 2 month prior study screen . Can comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adefovir dipivoxil</keyword>
	<keyword>e Antigen negative</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>Chinese</keyword>
</DOC>